DAFTAR PUSTAKA : PARADIGMA NASIONAL DI BIDANG

KESEHATAN DAN TANTANGANNYA DALAM

PENANGGULANGAN TB NASIONAL

1. (Intelijen, 01/IV/2009/22 April-05 Mei)

2. (www.hli.org/nssm 200 exposed.html).
3. Abednego H.M.M.: Kebijaksanaan baru dalam penanggulangan
tuberkulosis di Indonesia. Disampaikan pada Konggres VI Perhimpunan
Pemberantasan Tuberkulosis Indonesia (PPTI), Ciloto, 20-23 Nopember
1996.
4. Direktorat Jenderal PPM & PLP, Departemen Kesehatan: Gerakan
Terpadu Nasional Penanggulangan Tuberkulosis. Disampaikan pada
Seminar Sehari TB Paru Dalam rangka Peringatan Hari TB Sedunia ke
117, Jakarta, Mei 1999.)
5. The Indonesian Association of Pulmonologists: Hasil Konperensi Kerja
VIII Perhimpunan Dokter Paru Indonesia, Jakarta, 26-29 November
1998.
6. Aditama TY. DOTS & DOTS Plus. Temu Ilmiah Respirologi. Surakarta.
2001.
7. www.who.int/gtb/policyrd/DOTS.htm.
8. Perhimpunan Dokter Paru Indonesia. Pedoman penatalaksanaan TB paru.
1998.
9. www.who.int/gtb/policyrd/DOTS.tb. Otsuga Katsunori. JICA Project.
10.Terobosan Menuju Akses Universal Strategi Nasional Pengendalian TB
Di Indonesia 2010-2014,

11.Rapid Implementation of New TB Diagnostic Tests: Is It Too Soon

for a Global Roll-Out of Xpert MTB/RIF? Daniela E. Kirwan*,
María Kathia Cárdenas and Robert H. Gilman
12.Rapid molecular TB diagnosis: evidence, policy making and global
implementation of Xpert MTB/RIF. Karin Weyer, Fuad Mirzayev,
Giovanni Battista Migliori, Wayne Van Gemert, Lia D'Ambrosio,
Matteo Zignol, Katherine Floyd, Rosella Centis, Daniela M. Cirillo,
Enrico Tortoli, Chris Gilpin, Jean de Dieu Iragena, Dennis Falzon,
Mario RaviglioneEuropean Respiratory Journal 2013 42: 252-271
13.International Standards for Tuberculosis Care Edition 3, 2014
14.Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB
assay in China. Pang Y1, Dong H2, Tan Y3, Deng Y4, Cai X3, Jing
H4, Xia H1, Li Q1, Ou X1, Su B3, Li X4, Zhang Z2, Li J2, Zhang J2,
Huan S5, Zhao Y1.

15. Evaluation of the Cepheid Xpert MTB/RIF Assay for Direct

Detection of Mycobacterium tuberculosis Complex in Respiratory
Specimens

16. Role of Bleach Sedimentation to Improve the Accuracy of Sputum

Smear Microscopy for Diagnosing Tuberculosis . Abdul Sattar , Shahid
Habib Ansari, Mudasar Hussain,Muzaffar Masood, Abrar Anwar, Ali
Raza

17. Acquired Drug Resistance in Mycobacterium tuberculosis and Poor

Outcomes among Patients with Multidrug-Resistant Tuberculosis
Russell R. Kempker, Maia Kipiani, Veriko Mirtskhulava, Nestani
Tukvadze, Matthew J. Magee, and Henry M. Blumberg

18. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis

among over 500 consecutive patients. K. J. M. Aung,* A. Van Deun,E. Declercq,M.
R. Sarker,* P. K. Das,* M. A. Hossain,* H. L. Riede. INT J TUBERC LUNG DIS
18(10):1180–1187).).

19. World Health Organization. Guidelines for the Programmatic

Management of Drug-resistant Tuberculosis: 2016 Geneva, World Health
Organization, 2016.

20. Fixed-dose combination antituberculosis therapy: a systematic review

and meta-analysis. Amr S. Albanna, Benjamin M. Smith, Deanna Cowan,
Dick Menzies.European Respiratory Journal 2013 42: 721-732

21.Oosterhout JJ, Dzinjalamala FK, Dimba A, Waterhouse D, Davies G,

Ziljstra EE, et al. Pharmacokinetics of antituberculosis Drugs in HIV-
positive and HIV-negative adults in Malawi. Antimicrob Agents Chemother.
2015 Oct; 59(10): 6175–6180.
 22. Van Ingen J, Aarnoutse RE, Donald PR, Diacon AH, Dawson R.
Plemper van Balen G, et al. Why do we use 600 mg of rifampicin in
tuberculosis treatment? Clin Infect Dis. 2011;52(9):e194–9.

23. van Creel R, Alisjabana B, de Lange WC, Borst F, Danusantoso H, van

der Meer JW, et al. Low plasma concentrations of rifampicin in tuberculosis
patients in Indonesia. Int J Tuberc Lung Dis. 2002 Jun;6(6):497-502.

24. Treating drug sensitive tb in india: implementation of daily therapy with

fixed dose combinations. Policy Brief March 2015. Downloaded from:
https://www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/T
B_Briefing_FDC_Daily_regimen_India_eng_2015.pdf

25. MAMS-TB study finds high-dose rifampicin may help shorten TB

treatment. 10 Juni 2013. Downloaded from:
http://www.ctu.mrc.ac.uk/news/2015/mams_tb_results_01042015

26.WHO now charging fees for drug prequalifications, raising access fears.
18 September 2013. Downloaded from http://www.geneve-int.ch/who-now-
charging-fees-drug-prequalification-raising-access-fears

27. Stahl M. The WHO Prequalification of Medicines Programme. From:

CPTR 2013 Workshop. Washington, 2013: WHO

28. PQM Good Manufacturing Practices Baselines Assessments, Indonesia.

USAID. Downloaded from: http://pdf.usaid.gov/pdf_docs/Pdacr766.pdf

29. Jnawali HM, Ryoo SW. First and second line drugs and drug resistance,
tuberculosis. In: InTech, DOI: 10.5772/54960. Available from:
http://www.intechopen.com/books/tuberculosis-current-issues-in-diagnosis-
and-management/first-and-second-line-drugs-and-drug-resistance

30. Horsburgh Jr CR. Epidemiology, treatment and prevention of MDR-TB.

Downloaded from: https://medschool.vanderbilt.edu/tb-center/files/tb-
center/public_files/2_%20Final%20Horsburgh.pdf

31. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM,
et al. Population based resistance of Mycobacterium tuberculosis isolates to
 pyrazinamide and fluoroquinolones: results from a multicountry surveilence
project. Lancet Infect Dis. 2016 Oct; 16(10): 1185–1192.

32. D’Ambrosio L, Centis R, Sotgiu G, Pontali E, Spanevello A, Migliori

GB. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open
Research 2015 1: 00010-2015

33. Schaaf HS. Second-line TB drugs: ‘It is more difficult to assess adverse
effects in children’ Downloaded from: http://www.thehindu.com/sci-
tech/secondline-tb-drugs-it-is-more-difficult-to-assess-adverse-effects-in-
children/article5422109.ece

34. Sloan DJ, Lewis JM. Management of multidrug-resistant TB: novel

treatments and their expansion to low resource settings. Trans R Soc Trop
Med Hyg (2016) 110 (3): 163-172. doi: 10.1093/trstmh/trv107

35. National Institute of Health. Testimony of the FY 2008 budget request

before the senate committee. From: https://www.nih.gov/about-nih/who-we-
are/nih-director/fy-2008-directors-budget-request-statement

36. Bonnet M, Ramsay A, Githui W, Gagnidze L, Varaine F, Guerin PJ.

Bleach sedimentation: an opportunity to optimize smear microscopy for
tuberculosizs diagnosis in settings of high prevalence of HIV. Clin Infect
Dis. (2008) 46 (11): 1710-1716. doi: 10.1086/587891

37. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrug-

resistant tuberculosis not due to noncompliance but to between-patient
pharmacokinetic variability. J Infect Dis. 2011 Dec 15;204(12):1951-9. doi:
10.1093/infdis/jir658. Epub 2011 Oct 21.

38. Alcorn K. Dosing of key TB drug rifampicin could go higher.

Downloaded from: http://www.aidsmap.com/Dosing-of-key-TB-drug-
rifampicin-could-go-higher/page/2590198/

39. Smart T. High-dose rifampicin for TB treatment regimen may improve survival in
people with low CD4 cell counts. Downloaded from: http://www.aidsmap.com/High-
dose-rifampicin-for-TB-treatment-regimen-may-improve-survival-in-people-with-low-
CD4-cell-counts/page/3074652/
40. Menzies D, Elwood K. Treatment of tuberculosis disease. In:
Canadian tuberculosis standards. 7th ed. Public Health Agency of Canada.
Downloaded from: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/tb-
canada-7/tb-standards-tb-normes-ch5-eng.php